A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.

Clive R Taylor¹, Anagha P Jadhav², Abhi Gholap³, Gurunath Kamble², Jiaoti Huang⁴, Allen Gown⁵, Isha Doshi³, David L Rimm⁶

¹Department of Pathology, University of Southern California, Los Angeles.

²OptraSCAN, Pune, India.

³OptraSCAN, Sunnyvale, CA.

⁴Department of Pathology, Duke University School of Medicine, Durham, NC.

⁵PhenoPath, Seattle, WA.

⁶Department of Pathology, Yale University School of Medicine, New Haven, CT.

PubMed DOI

Abstract

Assessment of programmed death-ligand 1 (PD-L1) expression is a critical part of patient management for immunotherapy. However, studies have shown that pathologist-based analysis lacks reproducibility, especially for immune cell expression. The purpose of this study was to validate reproducibility of the automated machine-based Optra image analysis for PD-L1 immunohistochemistry for both tumor cel…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.